Skip to content
sellWeak10b5-1 plan

Tsveta Milanova sold $90k of AGIO

Chief Commercial Officer at AGIOS PHARMACEUTICALS, INC.. 2,804 shares at an average of $32.18, traded Jan 6, 2025, filed Jan 7, 2025.

Warning score
0
Value
$90k
2,804 shares
Holdings after
18,906
-13% from before
From 52-week low
+5%
low $31.84, close $33.54
From 52-week high
-46%
high $61.64, as of Jan 6, 2025

Score components

  • Role
    Officer
    +15
  • Trade size
    $90k at market
    +9
  • Share of holdings sold
    Sold 13% of holdings
    +5
  • Cluster
    No other insider selling within 14 days
    0
  • Exercise and sell
    Shares came from an option exercise in the same filing
    -15
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

AGIOOct 9, 2026 · close 31.81
Since filing Jan 7, 2025: -9.4%SPY +34.9% · excess -44.3%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001439222-25-000002, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Jan 3, 2025MOption exercise
Common stock10b5-1
+8,476$0.00$021,710Jan 7, 2025
Jan 6, 2025SOpen-market sale
Common stock10b5-1
-2,804$32.18$90k18,906Jan 7, 2025
Jan 3, 2025MOption exercise
Restricted stock unitsderivative10b5-1
-8,476$0.00$08,475Jan 7, 2025

Related signals

Other insiders at AGIOS PHARMACEUTICALS, INC. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
30Weak
AGIOsell 510b5-1
AGIOS PHARMACEUTICALS, INC.
Brian Goff
Chief Executive Officer
$627k
18,700 shares
-16%
5Weak
AGIOsell 510b5-1
AGIOS PHARMACEUTICALS, INC.
Tsveta Milanova
Chief Commercial Officer
$93k
2,770 shares
-10%
9Weak
AGIOsell 510b5-1
AGIOS PHARMACEUTICALS, INC.
Cecilia Jones
Chief Financial Officer
$60k
1,780 shares
-6%
5Weak
AGIOsell 510b5-1
AGIOS PHARMACEUTICALS, INC.
Sarah Gheuens
Chief Medical Officer
$98k
2,909 shares
-5%
5Weak
AGIOsell 510b5-1
AGIOS PHARMACEUTICALS, INC.
James William Burns
Chief Legal Officer
$94k
2,799 shares
-9%
0Weak
AGIOsell10b5-1
AGIOS PHARMACEUTICALS, INC.
Jacqualyn A Fouse
director
$194k
7,497 shares
-5%
12Weak
AGIOsell 610b5-1
AGIOS PHARMACEUTICALS, INC.
Theodore James Washburn Jr.
Principal Accounting Officer
$59k
1,655 shares
-26%
6Weak
AGIOsell 610b5-1
AGIOS PHARMACEUTICALS, INC.
Sarah Gheuens
Chief Medical Officer
$142k
4,005 shares
-8%
27Weak
AGIOsell 610b5-1
AGIOS PHARMACEUTICALS, INC.
Brian Goff
Chief Executive Officer
$460k
12,947 shares
-15%
2Weak
AGIOsell 610b5-1
AGIOS PHARMACEUTICALS, INC.
Tsveta Milanova
Chief Commercial Officer
$60k
1,681 shares
-7%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Tsveta Milanova sold $90k of AGIO | InsiderTell